Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Rush University Medical Center
Conditions and Treatments
Search by Topic or Doctor's Name
Doctors at Rush Focus on You
At the end of the visit, my goal is to have the patients feel more informed and to feel like their issues have been properly addressed.
— Octavio Vega, MD, internist
I enjoy the challenges of piecing together the puzzle – putting difficult, complicated signs and symptoms together and trying to formulate a diagnosis.
— Patricia Graham, MD, internist
Hear more from doctors at Rush.
Directions and Parking
Health & Wellness
Health News and Advice to Fit Your Life
The choices you make each day can have a huge effect on your health. Rush offers a wealth of resources to help you make good ones.
5 Things You Can Do to Prevent CancerHow you can devise a cancer prevention action plan.
Combating Social Media DysmorphiaHow to love yourself — and your selfies — without filters or fillers.
About RushThe Rush SystemPatient StoriesNational Recognition and AccreditationsRush News
Quality and Safety at RushPatient Satisfaction and FeedbackRush in the CommunityDiversity and Inclusion
Disability Rights and AccommodationsCommitment to LGBTQ Health CareVolunteeringBondholder Information
Study for the treatment of moderate to severe overactive bladder with urgency and incontinence
Clinical trial with combination therapies in immuno-oncology in advanced renal cell carcinoma.
Chronic kidney disease in offspring of diabetic gestation.
A phase 3 randomized study comparing perioperative nivolumab vs observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).
An open-label, randomized phase 3 study to evaluate enfortumab vedotin vs chemotherapy in subjects with previously treated locally advanced or metastatic urothelial cancer (EV-301).
An open-label, randomized, controlled, multicenter, phase II study evaluating safety and efficacy of intratumorally administered intuvax pre-nephrectomy followed by sunitinib post-nephrectomy, compared to sunitinib post-nephrectomy in mRCC.
A phase 3 study of erdafitinib compared to vinflunine or docetaxel or pembrolizumab in subjects with advanced urothelial cancer and selected FGFR gene aberrations.